Owlet faced intense regulatory scrutiny and compliance challenges when the U.S. Food and Drug Administration (FDA) issued a warning letter stating that its Smart Sock functioned as an unauthorized medical device due to its vital sign tracking and alert features. Additionally, the company experienced severe downward pressures on its stock valuation, briefly falling below minimum market capitalization thresholds required by the New York Stock Exchange, though management subsequently navigated regulatory clearances and regained compliance.